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CANCER
CANCER—Clinical Outcomes Studies
PCN1
EPOETIN ALFA AND DARBEPOETIN ALFA ANEMIA
TREATMENT OUTCOMES IN CANCER PATIENTS FROM A 
VA PERSPECTIVE
Papatheofanis FJ1, Fastenau JM2, Chiang T1, Piech CT2
1Aequitas, Carlsbad, CA, USA; 2Ortho Biotech Products, L.P,
Bridgewater, NJ, USA
OBJECTIVES: To compare dosing and treatment outcomes in
patients with cancer receiving epoetin alfa (EPO) and darbepo-
etin alfa (DARB). METHODS: Records across several clinical
and administrative data systems from adults receiving care in
outpatient VA practice settings were reviewed. Eligible patients
were required to have a cancer diagnosis, be ≥18 years, and have
a record of treatment with EPO or DARB for anemia (hemo-
globin (Hb) £11g/dL). RESULTS: A total of 2159 patients (1267
EPO, 892 DARB) were identiﬁed from November 2002–August
2003. Baseline characteristics such as age, gender, weight, tumor
type, percent receiving chemotherapy, baseline Hb, ECOG
status, transfusion use, and iron supplementation across groups
were all similar. Mean treatment duration was approximately 9
weeks (EPO: 57 days, DARB: 68 days). Mean weekly doses were:
EPO 35,337IU, DARB 108mcg. Mean cumulative doses were:
EPO 286,040IU, DARB 1036mcg. Based on average wholesale
price (AWP, Red Book 2003), weekly and cumulative treatment
costs were lower for EPO (EPO: $472/week, $3820/episode;
DARB: $539/week, $5170/episode; respectively). Hb change
from baseline independent of observed transfusion was signiﬁ-
cantly greater for EPO compared to DARB at all assessments
(Wk 4: 0.56 vs. 0.33g/dL, p < 0.0001; Wk 8: 0.76 vs. 0.46g/dL,
p < 0.0001; Wk 12: 0.93 vs. 0.64g/dL, p < 0.0001; respectively).
Cumulative hematologic effect, assessed by area under the Hb
change curve, was also greater for EPO (7.2 vs. 4.5g/dL). CON-
CLUSIONS: Results show greater early and overall hematologic
outcomes with EPO compared to DARB at lower treatment costs
suggesting dominance.
PCN2
IMPACT OF CHEMOTHERAPY-INDUCED DIARRHEA ON
MANAGEMENT PATTERNS AND RESOURCE UTILIZATION
AMONG CANCER PATIENTS: RESULTS FROM A MULTI-SITE
STUDY
Arnold RJ1, Gabrail N2, Raut M3, Kim R1, Sung J3, Gause D3,
Zhou Y1
1Pharmacon International, Inc, New York, NY, USA; 2Nashat Y. Gabrail,
Canton, OH, USA; 3Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA
OBJECTIVES: Diarrhea is a signiﬁcant dose-limiting toxicity
associated with chemotherapy treatment among cancer patients.
The objective of this study was to describe the demographic, clin-
ical, and management pattern characteristics of patients who
experience chemotherapy-induced diarrhea (CID) and assess the
impact of CID on resource utilization. METHODS: We con-
ducted a retrospective chart review of 378 cancer patients, d18
years, who experienced diarrhea during their chemotherapy
treatment between 2000 and 2003 from 25 community oncol-
ogy centers throughout the US. Demographic characteristics,
severity of diarrhea, and changes to chemotherapy treatment due
to diarrhea were evaluated using descriptive analysis. Compar-
isons of planned chemotherapy therapy versus actual chemother-
apy received by patients due to diarrhea and impact of CID on
anti-diarrheal medications, inpatient hospitalization and outpa-
tient visits were examined. RESULTS: Patients enrolled were
mostly white (80%) and middle-aged (mean 67 years). The most
common chemotherapy regimen received was 5-ﬂuorouracil
intravenous push + leukovorin (27%). There was a mean of 3.9
diarrheal episodes per patient. Patients who experienced CID
underwent signiﬁcant changes in their chemotherapy treatment,
including dose reductions (45%), delays in therapy (71%), and
reduction in dose intensity (64%). Treatment with anti-diarrheal
medications was done largely at home (74.9%) followed by
during ofﬁce visits (29.6%). Forty-four percent (n = 166) of the
study population had at least one CID related outpatient visit.
Mean number of outpatient visits for CID per patient was 2.5 +
2.5. Fifty-six patients (14.8%) experienced a CID-related hospi-
talization during the study time frame. CONCLUSIONS: The
study results showed that a signiﬁcant number of patients expe-
riencing CID required changes (usually reductions) to their
chemotherapy treatment, which may ultimately impact patient
clinical outcomes. CID also had a substantial impact on resource
utilization, which may translate into a considerable economic
burden.
PCN3
POTENTIAL IMPACT OF WANING OF VACCINE-INDUCED
IMMUNITY AGAINST HUMAN PAPILLOMAVIRUS 16/18
Goldie S1, Kohli M2, Grima D2,Weinstein MC1,Wright T3, Bosch F4,
Franco E5
1Harvard School of Public Health, Boston, MA, USA; 2Innovus
Research Inc, Burlington, ON, Canada; 3Columbia University, New
York, NY, USA; 4Institut Catala D’Oncologia, Barcelona, Spain; 5McGill
University, Montreal, QC, Canada
OBJECTIVES: To assess the comparative clinical beneﬁts asso-
ciated with HPV 16/18 vaccination when different assumptions
are made about the duration of efﬁcacy and the natural history
of detectable HPV 16/18 in women over 30. METHODS: A
computer-based model of cervical cancer simulates HPV 16/18
vaccination in a cohort of 12 year olds. We evaluated the impact
of waning after 5, 10, and 15 years on the effectiveness of a
vaccine that prevents 90% of persistent HPV 16/18 using alter-
native assumptions about the relative proportion of HPV infec-
tions in women over the age of 30 attributable to new acquisition
of HPV versus reactivation of latent or previously acquired HPV.
RESULTS: When we assumed that 50% of HPV infections in
older women are attributable to new acquisition of HPV, the
overall reduction in cancer varied from 54% with no waning, to
26%, 31%, and 36%, with waning after 5, 10, and 15 years,
respectively. As the proportion of persistent HPV infections
attributable to new (versus latent) infections was varied from
75% to 25% the overall reduction in cancer with waning at 5
years ranged from 16% to 36%; at 10 years ranged from 21%
to 41%, and at 15 years ranged from 28% to 48%. CONCLU-
SION: There are dramatic differences in the relative effects 
of waning when adopting different assumptions about the 
proportion of persistent HPV infection attributable to new
(versus latent) infections in older women, highlighting the high
priority that should be placed on empiric data to inform such
assumptions.
PCN4
TECHNOLOGY ADVANCES AND TREATMENT PATTERN
VARIATIONS IN ONCOLOGY: EVIDENCE FROM USE OF 
CPT-11 IN ELDERLY METASTATIC COLORECTAL CANCER
PATIENTS
Shih YCT
The University of Texas M.D. Anderson Cancer Center, Houston,TX,
USA
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OBJECTIVE: Technology advances have introduced many novel
oncology drugs to the market recently. Economic models com-
paring chemotherapy drugs often assumed similar treatment
pattern (e.g., same duration in best supportive care (BSC)) fol-
lowing the completion/discontinuity of chemotherapy. This study
explores the association between technology advances and treat-
ment patterns by examining utilization patterns among Medicare
beneﬁciaries with metastatic colorectal cancer (MCRC) when a
new technology irinotecan (CPT-11) became available in 1999.
METHODS: A sample of chemo-treated MCRC patients diag-
nosed after January 1, 1998 and died before December 31, 2001
was selected from the SEER-Medicare data. A multivariate logis-
tic model was used to examine factors associated with receiving
CPT-11. The course of cancer treatment was categorized as pre-
chemotherapy, chemotherapy, and post-chemotherapy (i.e., BSC)
stages. T-test was used to compare the duration at each stage for
patients who received CPT-11 vs. those who did not. RESULTS:
The study sample included 627 chemo-treated MCRC patients.
Among patients with identiﬁable chemotherapy regimens (N =
477), 45.6% had at least one claim indicative of CPT11 (J9206).
The logistic model showed that compared with patients in the
age group 65–69, those in the age group 75–79 (OR = 0.42; P
= 0.008) and > = 80 (OR = 0.33; P = 0.001) were signiﬁcantly
less likely to receive CPT-11. No gender (OR = 1.36; P = 0.13)
or racial difference (OR = 1.1; P = 0.76) was found. Compared
with the non-users, the CPT-11 group had longer survival (547
vs. 359 days, P < 0.0001), longer time on chemotherapy (398 
vs. 164; P < 0.0001) and shorter time in BSC (75 vs. 122; P =
0.0006). No difference was found in the pre-chemo duration (73
vs. 70; P = 0.86). CONCLUSIONS: New technology appears to
have changed the time allocation in different treatment stages in
cancer; it lengthens the duration of chemotherapy and shortens
that of BSC. The observed survival difference in this study needs
to be interpreted with caution as it may be subject to sample
selection bias.
PCN5
ANALYSIS OF OVER 2400 MODERN PHASE I CANCER TRIALS:
COMPOSITION, OUTCOMES,AND USE OF SURROGATE
ENDPOINTS
Roberts TG1, Goulart BHL1, Stallings SC2, Squitieri L2, Chabner BA1,
Finkelstein SN2, Clark JW1
1Massachusetts General Hospital, Boston, MA, USA; 2Massachusetts
Institute of Technology, Cambridge, MA, USA
OBJECTIVES: There has been no comprehensive analysis of
phase I cancer trials since 1991, despite the transition from cyto-
toxic to targeted drugs. Trends in response rates (RR) and toxic
death rates (TDR) for modern phase I trials are therefore
unknown. We set out to perform the most extensive outcomes
analysis to date of phase I cancer trials. METHODS: We ana-
lyzed the composition and outcomes of all phase I cancer trials
submitted to meeting of the American Society of Clinical
Oncoloy for years 1991 through 2002. For trials testing unap-
proved, single-agents in solid tumors, we reviewed published
reports and performed patient-level analysis. The major out-
comes variables included overall response rate (RR) and toxic
death rate (TDR). We also analyzed the use of biomarkers (BM)
and surrogate endpoints (SE). RESULTS: The overall data set
included 2439 trials. Over the period of analysis, phase I trials
have become signiﬁcantly more international, more complex in
design, and more likely to identify a commercial sponsor. Drugs
under investigation have become more likely to be given by the
oral route, less likely to be produced by recombinant technol-
ogy, and less likely to be cytotoxic. The strongest predictor for
inclusion of a BM or SE was NIH sponsorship (odds ratio, 2.9).
The overall RR and TDR for single-agent studies published in
ﬁnal form was 3.96% and 0.6%, respectively. Both RR and TDR
fell signiﬁcantly over the period. In linear regression models, RR
fell from 8.0% in 1991 to 2.4% in 2001; but the fall in TDR
was more pronounced over the same period. Signiﬁcantly higher
RRs and TDRs were seen among cytotoxic drugs as compared
to targeted and biologic agents. CONCLUSIONS: The compo-
sition and design of phase I cancer trials is changing. Although
overall RRs have declined, the risk/beneﬁt ratio for patients may
be improving.
PCN6
FACTORS INFLUENCING PHYSICIAN RECOMMENDATION
FOR IMATINIB MESYLATE IN CHRONIC PHASE CHRONIC
MYELOID LEUKEMIA (CML) PATIENTS
Iyer SS, Doucette WR
University of Iowa, Iowa City, IA, USA
OBJECTIVE: The use of imatinib mesylate as ﬁrst line treatment
in management of chronic phase chronic myeloid leukemia
(CML) is controversial. The objective of this study was to
examine signiﬁcant inﬂuences on physician recommendation for
imatinib mesylate in chronic phase CML patients. METHODS:
Data were collected via e-mail and web-based survey from a
random sample of 1100 hematologists/oncologists listed in 
the American Society of Clinical Oncology (ASCO) database.
Rogers’ model of adoption of innovations was used as the main
framework for the study. A series of pre-tested vignettes varying
patient age and disease severity were used to assess physician rec-
ommendations to treat with imatinib vs. bone marrow trans-
plant. A visual analog scale was used to measure physicians’
recommendations. The main survey procedure used a modiﬁed
Dillman’s method. Factor analysis was performed for appropri-
ate measures. Multiple regression analysis was used to test the
model. Based on the theoretical model, the categories of inde-
pendent variables included: innovation characteristics, commu-
nication channels, physician characteristics, social system
characteristics and control variables. A within subjects repeated
measures analysis was conducted to study the inﬂuence of pa-
tient age and disease severity on physician recommendation.
RESULTS: A total of 305 responses were received giving a
response rate of 29%. The regression model was found to be sig-
niﬁcant (p < 0.05). Perceived relative advantage of imatinib in
efﬁcacy, peer inﬂuence, past experience and academic afﬁliation
were found to be signiﬁcant positive inﬂuences. Specialty in bone
marrow transplantation was found to be a signiﬁcant negative
inﬂuence. Physicians were found to recommend imatinib mesy-
late to a greater extent in patients at least 55 years old as com-
pared to younger ones. CONCLUSION: Rogers’ model of
adoption of innovation is useful in explaining physician recom-
mendation for imatinib mesylate. In addition, patient age is a
signiﬁcant inﬂuence on physician recommendation for imatinib
mesylate.
CANCER
CANCER—Cost Studies
PCN7
TRENDS IN CHEMOTHERAPY USE, OUTCOMES,AND COST
FOR PATIENTS WITH ADVANCED NONSMALL LUNG
CANCER: EVIDENCE FROM SEER-MEDICARE
Ramsey SD, Etzioni RD, Howlader N,Abullarade J
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
OBJECTIVES: Clinical trials suggest that chemotherapy offers a
modest survival advantage in advanced nonsmall cell lung cancer
